Eli Lilly and Company (LLY)
Pre-market: 06:11AM EDT
| Previous close | 238.98 |
| Open | 239.06 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 239.06 - 242.55 |
| 52-week range | 129.21 - 275.87 |
| Volume | 1,309,002 |
| Avg. volume | 2,537,241 |
| Market cap | 231.789B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 36.44 |
| EPS (TTM) | 6.65 |
| Earnings date | 26 Oct 2021 |
| Forward dividend & yield | 3.40 (1.42%) |
| Ex-dividend date | 12 Aug 2021 |
| 1y target est | N/A |
- Zacks
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk
Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from Eli Lilly and Company's (NYSE: LLY) SURPASS-4 clinical trial, which were published today in The Lancet. At 52 weeks, the highest dose of tirzepatide led to an A1C reduction of 2.58 percent and reduced body weight by 11.7 kg (-25.8 lb., -13.0 percent) compared to re
- PR Newswire
Lilly Declares Fourth-Quarter 2021 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock.
